Natera (NTRA) Lifted to “Sell” at BidaskClub

Natera (NASDAQ:NTRA) was upgraded by investment analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a research note issued on Friday.

Other equities analysts also recently issued research reports about the stock. Piper Jaffray Companies boosted their price target on shares of Natera to $27.00 and gave the stock an “overweight” rating in a research note on Thursday, August 9th. Zacks Investment Research downgraded shares of Natera from a “hold” rating to a “sell” rating in a research note on Wednesday, October 10th. TheStreet downgraded shares of Natera from a “c-” rating to a “d+” rating in a research note on Tuesday, October 9th. Craig Hallum boosted their target price on shares of Natera from $23.00 to $30.00 and gave the stock a “buy” rating in a research note on Thursday, August 9th. Finally, Cowen reiterated a “buy” rating and set a $30.00 target price on shares of Natera in a research note on Friday, November 9th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. Natera currently has an average rating of “Buy” and an average target price of $28.25.

NASDAQ:NTRA opened at $17.69 on Friday. The firm has a market capitalization of $1.08 billion, a price-to-earnings ratio of -7.37 and a beta of 2.03. The company has a debt-to-equity ratio of 1.30, a current ratio of 2.44 and a quick ratio of 2.32. Natera has a 52 week low of $8.60 and a 52 week high of $29.62.



Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Thursday, November 8th. The medical research company reported ($0.49) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.46) by ($0.03). The business had revenue of $65.30 million during the quarter, compared to analyst estimates of $66.42 million. Natera had a negative return on equity of 2,569.52% and a negative net margin of 58.00%. The business’s revenue was up 16.8% on a year-over-year basis. During the same quarter last year, the firm earned ($0.51) EPS. On average, sell-side analysts anticipate that Natera will post -2.11 earnings per share for the current fiscal year.

In related news, COO Steven Leonard Chapman sold 35,000 shares of the business’s stock in a transaction on Friday, October 12th. The shares were sold at an average price of $20.66, for a total transaction of $723,100.00. Following the completion of the transaction, the chief operating officer now owns 24,240 shares in the company, valued at $500,798.40. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Jonathan Sheena sold 166,667 shares of the business’s stock in a transaction on Tuesday, October 16th. The stock was sold at an average price of $20.66, for a total transaction of $3,443,340.22. Following the transaction, the insider now owns 372,583 shares of the company’s stock, valued at approximately $7,697,564.78. The disclosure for this sale can be found here. In the last quarter, insiders have sold 2,014,988 shares of company stock valued at $48,674,710. Insiders own 13.18% of the company’s stock.

Hedge funds have recently modified their holdings of the stock. Pacer Advisors Inc. acquired a new position in shares of Natera during the third quarter worth $106,000. Point72 Hong Kong Ltd acquired a new position in Natera in the third quarter valued at $119,000. Quantbot Technologies LP acquired a new position in Natera in the third quarter valued at $135,000. Meeder Asset Management Inc. boosted its stake in Natera by 920.5% in the third quarter. Meeder Asset Management Inc. now owns 8,399 shares of the medical research company’s stock valued at $200,000 after acquiring an additional 7,576 shares in the last quarter. Finally, United Services Automobile Association acquired a new position in Natera in the third quarter valued at $214,000. Hedge funds and other institutional investors own 87.90% of the company’s stock.

About Natera

Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.

Read More: Why is the LIBOR significant?

Analyst Recommendations for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply